<?xml version='1.0'?><!DOCTYPE Annotation PUBLIC "//GENIA//DTD GENIA ANNOTATION EVENT 2.0//EN_Modified" "../ModifiedGENIAtypes/Modified_GENIA_event_20.dtd"><Annotation annotates="http://www.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&amp;retmode=xml&amp;rettype=medline&amp;id=10208867" created="19/05/2006" creator="Yo Shidahara"><PubmedArticleSet><PubmedArticle><MedlineCitation>
<PMID>10208867</PMID>
<Article>
<ArticleTitle>
<sentence id="S1"><term id="T1" lex="Angiotensin_II" sem="Protein_molecule">Angiotensin II</term> activates the <term id="T2" lex="proinflammatory_transcription_factor" sem="Protein_family_or_group">proinflammatory transcription factor</term> <term id="T3" lex="nuclear_factor-kappaB" sem="Protein_complex">nuclear factor-kappaB</term> in <term id="T4" lex="human_monocyte" sem="Cell_natural">human monocytes</term>.</sentence>
<event id="E1">
<type class="Positive_regulation"/>
<theme idref="T3"/>
<cause idref="T1"/>
<clue>Angiotensin II <clueType>activates</clueType> the proinflammatory transcription factor nuclear factor-kappaB <clueLoc>in human monocytes</clueLoc>.</clue>
</event>
</ArticleTitle>
<Abstract>
<AbstractText>
<sentence id="S2">The <term id="T5" lex="renin-angiotensin_system" sem="Other"><term id="T6" lex="renin" sem="Protein_molecule">renin</term>-<term id="T7" lex="angiotensin" sem="Peptide">angiotensin</term> system</term> may contribute to the pathogenesis of <term id="T8" lex="atherosclerosis" sem="Other">atherosclerosis</term>.</sentence>
<event KT="Other" id="E2">
<type/>
<theme idref="T8"/>
<cause idref="T8"/>
<clue>The renin-angiotensin system may contribute to the <clueType>pathogenesis</clueType> <linkCause>of</linkCause> atherosclerosis.</clue>
<comment>SOO</comment></event>
<event CL="L1" KT="Analysis" id="E3" uncertainty="probable">
<type class="Correlation"/>
<theme idref="T5"/>
<theme idref="E2"/>
<clue>The renin-angiotensin system <clueKT><clueCL>may</clueCL></clueKT> <clueType>contribute</clueType> <linkTheme>to</linkTheme> the pathogenesis of atherosclerosis.</clue>
</event>
<sentence id="S3">A common feature of all stages of <term id="T9" lex="atherosclerosis" sem="Other">atherosclerosis</term> is <term id="T10" lex="inflammation" sem="Other">inflammation</term> of the <term id="T11" lex="vessel_wall" sem="Tissue_natural">vessel wall</term>.</sentence>
<sentence id="S4">The transcription factor <term id="T12" lex="nuclear_factor-kappaB" sem="Protein_complex">nuclear factor-kappaB</term> (<term id="T13" lex="NF-kappaB" sem="Protein_complex">NF-kappaB</term>) participates in most <term id="T14" lex="signaling_pathway" sem="Other">signaling pathways</term> involved in <term id="T15" lex="inflammation" sem="Other">inflammation</term>.</sentence>
<event KT="Other" id="E4">
<type class="Positive_regulation"/>
<theme idref="T15"/>
<cause idref="T14"/>
<clue>The transcription factor nuclear factor-kappaB (NF-kappaB) participates in most signaling pathways <clueType>involved</clueType> <linkTheme>in</linkTheme> inflammation.</clue>
</event>
<event KT="Fact" id="E5">
<type class="Positive_regulation"/>
<theme idref="E4"/>
<cause idref="T13"/>
<clue>The transcription factor nuclear factor-kappaB (NF-kappaB) <clueType>participates</clueType> <linkTheme>in</linkTheme> most signaling pathways involved in inflammation.</clue>
</event>
<sentence id="S5">This study therefore examined the effect of <term id="T16" lex="angiotensin_(ANG)_II" sem="Protein_molecule">angiotensin (ANG) II</term> on <term id="T17" lex="NF-kappaB_activation" sem="Other"><term id="T18" lex="NF-kappaB" sem="Protein_complex">NF-kappaB</term> activation</term> in <term id="T19" lex="monocytic_cell" sem="Cell_natural">monocytic cells</term>, a major cellular component of <term id="T20" lex="human_atheroma" sem="Tissue_natural">human atheroma</term>, by <term id="T21" lex="electrophoretic_mobility_shift_assay" sem="Other">electrophoretic mobility shift assay</term>.</sentence>
<event KT="Other" id="E6">
<type class="Positive_regulation"/>
<theme idref="T18"/>
<clue>This study therefore examined the effect of angiotensin (ANG) II on NF-kappaB <clueType>activation</clueType> in monocytic cells, a major cellular component of human atheroma, by electrophoretic mobility shift assay.</clue>
</event>
<event KT="Investigation" id="E7" uncertainty="doubtful">
<type class="Regulation"/>
<theme idref="E6"/>
<cause idref="T16"/>
<clue>This study therefore <clueKT>examined</clueKT> the <clueType>effect</clueType> <linkCause>of</linkCause> angiotensin (ANG) II <linkTheme>on</linkTheme> NF-kappaB activation in monocytic cells, a major cellular component of human atheroma, <clueExperiment>by electrophoretic mobility shift assay</clueExperiment>.</clue>
</event>
<sentence id="S6"><term id="T22" lex="ANG_II" sem="Protein_molecule">ANG II</term>, like <term id="T23" lex="TNFalpha" sem="Protein_molecule">TNFalpha</term>, caused rapid activation of <term id="T24" lex="NF-kappaB" sem="Protein_molecule">NF-kappaB</term> in <term id="T25" lex="human_mononuclear_cell" sem="Cell_natural">human mononuclear cells</term> isolated from <term id="T26" lex="peripheral_blood" sem="Tissue_natural">peripheral blood</term> by <term id="T27" lex="Ficoll_density_gradient" sem="Other">Ficoll density gradient</term>.</sentence>
<event Manner="High" id="E8">
<type class="Positive_regulation"/>
<theme idref="T24"/>
<cause idref="T22"/>
<clue>ANG II, like TNFalpha, <clueType>caused</clueType> <clueManner>rapid</clueManner> <clueType>activation</clueType> <linkTheme>of</linkTheme> NF-kappaB <clueLoc>in human mononuclear cells isolated from peripheral blood by Ficoll density gradient</clueLoc>.</clue>
</event>
<event Manner="High" id="E9">
<type class="Positive_regulation"/>
<theme idref="T24"/>
<cause idref="T23"/>
<clue>ANG II, like TNFalpha, <clueType>caused</clueType> <clueManner>rapid</clueManner> <clueType>activation</clueType> <linkTheme>of</linkTheme> NF-kappaB <clueLoc>in human mononuclear cells isolated from peripheral blood by Ficoll density gradient</clueLoc>.</clue>
</event>
<sentence id="S7">This <term id="T28" lex="ANG_II_effect" sem="Other"><term id="T29" lex="ANG_II" sem="Protein_molecule">ANG II</term> effect</term> was blocked by the <term id="T30" lex="angiotensin_AT1_receptor_antagonist" sem="Organic_compound_other">angiotensin AT1 receptor antagonist</term> <term id="T31" lex="losartan" sem="Organic_compound_other">losartan</term>.</sentence>
<event id="E10">
<type class="Negative_regulation"/>
<theme idref="E8"/>
<cause idref="T31"/>
<clue><corefTheme>This ANG II effect</corefTheme> was <clueType>blocked</clueType> <linkCause>by</linkCause> the angiotensin AT1 receptor antagonist losartan.</clue>
</event>
<sentence id="S8">Specificity of <term id="T32" lex="ANG_II" sem="Protein_molecule">ANG II</term>-induced <term id="T33" lex="NF-kappaB_activation" sem="Other"><term id="T34" lex="NF-kappaB" sem="Protein_complex">NF-kappaB</term> activation</term> was ascertained by <cons id="T35" lex="(AND supershift_experiment competition_experiment)" sem="(AND Other Other)"><frag id="F1">supershift</frag> and <frag id="F2">competition</frag> <frag id="F3">experiments</frag></cons>.</sentence>
<event KT="Other" id="E11">
<type class="Positive_regulation"/>
<theme idref="T34"/>
<clue>Specificity of ANG II-induced NF-kappaB <clueType>activation</clueType> was ascertained by supershift and competition experiments.</clue>
</event>
<event KT="Investigation" id="E12">
<type class="Positive_regulation"/>
<theme idref="E11"/>
<cause idref="T33"/>
<clue>Specificity of ANG II-<linkCause>induced</linkCause> NF-kappaB activation was <clueKT>ascertained</clueKT> <clueExperiment>by supershift and competition experiments</clueExperiment>.</clue>
</event>
<sentence id="S9">Moreover, <term id="T36" lex="ANG_II" sem="Protein_molecule">ANG II</term> stimulated <term id="T37" lex="NF-kappaB_activation" sem="Other"><term id="T38" lex="NF-kappaB" sem="Protein_complex">NF-kappaB</term> activation</term> in <term id="T39" lex="human_monocyte" sem="Cell_natural">human monocytes</term>, but not in <term id="T40" lex="lymphocyte" sem="Cell_natural">lymphocytes</term> from the same preparation.</sentence>
<event id="E13">
<type class="Positive_regulation"/>
<theme idref="T38"/>
<clue>Moreover, ANG II stimulated NF-kappaB <clueType>activation</clueType> in human monocytes, but not in lymphocytes from the same preparation.</clue>
</event>
<event id="E14">
<type class="Positive_regulation"/>
<theme idref="E13"/>
<cause idref="T36"/>
<clue>Moreover, ANG II <clueType>stimulated</clueType> NF-kappaB activation <clueLoc>in human monocytes</clueLoc>, but not in lymphocytes from the same preparation.</clue>
</event>
<event Polarity="Negative" assertion="non-exist" id="E15">
<type class="Positive_regulation"/>
<theme idref="E13"/>
<cause idref="T36"/>
<clue>Moreover, ANG II <clueType>stimulated</clueType> NF-kappaB activation in human monocytes, but <cluePolarity>not</cluePolarity> <clueLoc>in lymphocytes from the same preparation</clueLoc>.</clue>
</event>
<sentence id="S10">Together, the data demonstrate the ability of the <term id="T41" lex="vasoactive_peptide" sem="Peptide">vasoactive peptide</term> <term id="T42" lex="ANG_II" sem="Protein_molecule">ANG II</term> to activate <term id="T43" lex="inflammatory_pathway" sem="Other">inflammatory pathways</term> in <term id="T44" lex="human_monocyte" sem="Cell_natural">human monocytes</term>.</sentence>
<event CL="L2" KT="Analysis" id="E16">
<type class="Positive_regulation"/>
<theme idref="T43"/>
<cause idref="T42"/>
<clue>Together, the data <clueKT>demonstrate</clueKT> the <clueCL>ability</clueCL> of the vasoactive peptide ANG II to <clueType>activate</clueType> inflammatory pathways <clueLoc>in human monocytes</clueLoc>.</clue>
</event>
<sentence id="S11">Copyright 1999 Academic Press.</sentence>
</AbstractText>
</Abstract></Article></MedlineCitation></PubmedArticle></PubmedArticleSet></Annotation>
